Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …

Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population
worldwide. The characteristic white patches result from the selective loss of melanocytes …

Background Vitiligo, an autoimmune disorder characterised by skin depigmentation, is
associated with reduced quality of life (QoL). Vitiligo may be under‐reported, in part because …

Clinicians should be aware that vitiligo is not merely a cosmetic disease and that there are
safe and effective treatments available for vitiligo. It is important to recognize common and …

Vitiligo is a common autoimmune disease that progressively destroys melanocytes in the
skin, resulting in the appearance of patchy depigmentation. This disfiguring condition …

Background Patients with vitiligo experience reduced quality of life. Objective To
comprehensively describe the available evidence for psychosocial burden in vitiligo …

Melanin, the compound primarily responsible in humans for hair, eye and skin pigmentation,
is produced by melanocytes through a complicated process called melanogenesis that is …

Vitiligo is an autoimmune skin disease mediated by autoreactive CD8+ T cells that destroy
the pigment-producing cells of the epidermis, melanocytes, leading to areas of …

Despite historical mischaracterization as a cosmetic condition, patients with the autoimmune
disorder vitiligo experience substantial quality‐of‐life (QoL) burden. This systematic …

Vitiligo is an acquired chronic autoimmune (AI) pigmentation disorder resulting in patchy,
white, nonscaly macules and patches. The worldwide prevalence of the disease is estimated …